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According to the 2011 World Health Organization Global Status
Report, of the 57 million annual global deaths – a staggering 36 million or
over 63% are due to chronic diseases.1 Four noncommunicable diseases namely cardiovascular, cancer, diabetes, and chronic respiratory
diseases - emerge as the leading cause of mortality in the world,
accounting respectively for 17, 7.6, 4.2, and 1.3 million deaths based on
the latest available global epidemiology data. By 2020, global deaths due
to chronic diseases are projected to worsen by at least 15 to 20%. It is
estimated that the four major noncommunicable diseases will be
responsible for 75% of worldwide deaths by 2030.2
Progress to date on noncommunicable diseases has been vastly
inadequate at global scale, resulting in a rampant pandemic. As
described by the World Health Organization Director-General Margaret
Chan, “The rise of chronic noncommunicable diseases presents an
enormous challenge. For some countries, it is no exaggeration to describe
the situation as an impending disaster; a disaster for health, for society…”.3
Alarmingly, across all continents (with the exception of Africa),
deaths from noncommunicable diseases now exceed those from
communicable, maternal, perinatal and nutritional conditions combined.
For men in Europe, for example, deaths from noncommunicable diseases
are 13 times higher than other causes combined, and for men in the
Western Pacific region, they are 8 times higher. Remarkably, the burden of

chronic diseases is rising disproportionately among lower income countries
and populations, with nearly 80% of noncommunicable diseaseassociated deaths reported in low- and middle-income countries.1-3
Chronic diseases are an under-appreciated cause of poverty that
hinders the economic development around the world. The burden is
growing - the number of people, families and communities afflicted is
increasing. Noncommunicable diseases stand as a major barrier to
achievement of the anti-poverty Millennium Development Goals, with
urgent action required to integrate management of chronic diseases into
global health priorities.
Tackling the global noncommunicable diseases crisis requires a
concerted and coordinated multi-sectorial response, committed across
societies at large. This requires adapting health systems and health
policies,

and

a

shift

from

disease-centered

to

people-centered

approaches and population health measures. Vertical initiatives are
insufficient to meet complex population needs, so integrated solutions
that engage a matrix of disciplines and sectors are needed.1-3
Evidence-based and cost-effective interventions exist to prevent
and control the threat of chronic diseases at global, regional, national
and local levels. Modifiable risk factors, including tobacco, harmful use of
alcohol, unhealthy diet, insufficient physical activity, obesity, as well as
hypertension, hyperglycemia and hypercholesterolemia are recognized

as major contributors to the underlying pathobiology of chronic disease
processes.1-5 Comprehensive and integrated action at country/continent
level is thus mandatory to advance solutions in order to prevent morbidity
and disability. To this end, implementation of the World Health
Organization Action Plan for the Global Strategy for the Prevention and
Control of noncommunicable diseases, the Global Strategy on Diet,
Physical Activity and Health, and the Global Strategy to Reduce the
Harmful Use of Alcohol are all vital initiatives.1-3
Establishment of a United Nations 2012-2022 Decade of Action on
Noncommunicable Diseases has been advocated to ensure that 85% of
the world’s population has access to information, education and services
to reduce vulnerability and death rates associated with chronic diseases.
In this context, the Noncommunicable Diseases Alliance, steered by the
International

Diabetes

Federation,

the International

Union

against

Tuberculosis and Lung Disease, the Union for International Cancer Control
and the World Heart Federation, and representing over 900 professional
member organizations in 170 countries, has been at the forefront of
advocacy.6 Recommendations, at worldwide scale, include promotion of
population-wide prevention, early detection, screening, and awarenessraising programs for noncommunicable diseases targeting populations at
risk. This would include by 2013, development and implementation of
regulatory measures to achieve substantial reductions in levels of

saturated fats, trans-fats, salt and refined sugars in processed foods, as
well as to reduce worldwide salt intake.6 By 2018, the goal is to decrease
mortality and morbidity of cardiovascular diseases, diabetes, as well as
gastric, colorectal, breast, and cervical cancer by increasing early
detection,

implementing

immunization

strategies

for

human

papillomavirus and hepatitis B virus for populations at high risk, and
globally reducing environmental, occupational and contextual risk factors
associated with noncommunicable diseases.6 Ensuring universal access to
affordable, safe and effective, quality noncommunicable diseases
diagnosis and treatment, and further strengthening of national and
community-based health systems to enable continuity of care are indeed
paramount.
Transforming community and global health would further require
accelerated fundamental research to acquire new knowledge on
disease causes and cures, integrated across an effective translational
continuum of prevention, treatment and management for the spectrum
of chronic disease conditions.7 Leveraging discovery to the benefit of
patients and populations encompasses multiple integrated steps.8,9 By
addressing a global unmet need, initial discovery science leads to
development and evaluation of candidate health applications, followed
by validation and prescription of evidence-based recommendations for
clinical practice and health decision-making, and finally patient-centric

translation which strives to disseminate health care interventions integral
to

community

practices.8-12

Advancing

the

medical

model

of

‘intervention’ into the public health model of disease management or
‘prevention’ ultimately enables prevention and behavioral alterations in
communities and populations.8,9 The public health model focuses on
information and education programs that eliminate deleterious behaviors
at the community and population levels, associated with improved
disease prevention and reduced costs for medical care. The impact of
these paradigms must extend beyond individual communities, to translate
the maximum benefits of scientific and medical innovation to populations
at large. In this context, the public health model of care evolves into the
social health model, which focuses on improving the health of
populations by reforming suboptimal social structures enabling adequate
distribution of the products of scientific innovation to those global
populations in greatest need.8,9
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